PetLife Pharmaceuticals' CEO, Dr. Ralph Salvagno, Issues Letter to Shareholders
Management Expressing an Optimistic Outlook for PetLife Pharmaceuticals' Future
Hancock, Maryland, July 21, 2017 (Newswire.com) - PetLife Pharmaceuticals, Inc. (OTCQB: PTLF) (the “Company”), a developer of a new generation of high potency veterinary cancer medications and nutraceuticals for pets, has issued a letter to its shareholders from Ralph Salvagno, MD, CEO and Chairman of the Company, as follows:
Dear PetLife Pharmaceuticals Shareholder:
PetLife Pharmaceuticals, Inc. (“PetLife”) continues to make progress towards our goal of bringing effective, affordable and safe products to our companion animals and their pet families.
Our recent acquisition of Dr. Geoff’s pet food product line has the team working to build out the appropriate materials for test marketing and sales within the next 3 months. The team has worked to establish the manufacturing and distribution channels necessary for success as well as having identified strategic partners for advertising and promotion. PetLife Advisory Board member and world renown Veterinarian, Dr. Geoffrey Broderick, continues to promote the new brand, “Dr. Geoff’s by PetLife,” as well as drawing attention to the work being done by PetLife for the treatment of cancer through VITAZULTM.
We have engaged our in-country team for the development of our PetLife Scorpion Ranch. Scorpions have been collected and plans continue to have the ranch fully functional and extracting venom within 60-90 days. Venom is one of the world’s most precious liquids and is valued at over $7,000 /gm ($198,000/oz.). PetLife intends to use all its production of venom on proprietary PetLife products for the treatment of cancer and intends to continue research on Vitalzul™’s potential as a cancer preventative.
Management expresses its disappointment at the recent stock performance. We recognize that there are forces in play that hope to capitalize on the volatility in small cap markets. The Company also recognizes that the fundamentals of our research, our patent pending technology, our mission, and our team, should outweigh any short-term trends in stock price. PetLife will be “on the road” in the next several weeks to bring our message to investors on the west coast. The schedule of “road shows” will be published as soon as it is finalized.
The Company continues to investigate strategic partnerships that will enhance the mission and value of the Company. As these relationships develop beyond the discussion phase, the Company will make this information public, as appropriate. The Company is actively seeking partnerships in nutraceutical and complementary products. We recognize the unmet need for safe and effective products for treatment of arthritis, autoimmune and neuromuscular diseases and are working to develop solutions based on our patent pending technology.
On behalf of the PetLife team, I appreciate your continued support in our goal of improving the quality of life for our companion animals and the families that love them.
Ralph Salvagno, MD
CEO and Chairman
About PetLife Pharmaceuticals
PetLife Pharmaceuticals, Inc. (PTLF) (www.PetLifePharma.com) is a registered U.S. Veterinary Pharmaceutical company. PetLife’s mission is to bring its new, non-toxic, bioactive nutraceuticals and prescription medications to the world of veterinary oncology with the ultimate goal of preventing cancer and extending the life of pets suffering from cancer while improving their quality of life. The Company’s first product, Vitalzul™, is currently in testing. Vitalzul™’s active ingredients have been shown to have activity against several different cancer cell lines. In the U.S. alone, consumer spending on domestic companion animals reached over $60 billion in 2015 with over $29 billion spent on veterinary care and medications. PetLife’s acquired brand, Dr. Geoff’s Real Food for Pets, will launch in 2017. PetLife Scorpion Ranch™ will break ground in 2017. PetLife anticipates incorporating Vitalzul™ in a new and advanced therapeutic pet food line in 2019.
Forward looking statement:
This press release contains certain "forward-looking statements," as defined in the United States PSLRA of 1995, that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. The economic, competitive, governmental, technological and other factors identified in the Company's previous filings with the Securities and Exchange Commission may cause actual results or events to differ materially from those described in the forward-looking statements in this press release. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
844-473-8543 ext. 701
Source: PetLife Pharmaceuticals, Inc.